Literature DB >> 32182196

Non-opioid pharmacologic treatment of chronic spinal cord injury-related pain.

Mendel Kupfer1, Christopher S Formal1.   

Abstract

Purpose: Spinal cord injury-related pain is often a severe debilitating condition that adversely affects the patient's physical health, psychological wellbeing and quality of life. Opioid medications have historically been prescribed to this population with great frequency. As opioid abuse disorder becomes an ever-worsening public health issue, more attention must be placed upon non-opioid options. This paper reviews non-opioid medications to be considered when treating spinal cord injury-related pain. The pertinent literature is reviewed, and the advantages and pitfalls of various medication options are discussed in the complicated context of the individual with a spinal cord injury.
Methods: Peer-reviewed journal articles and medication package insert data are reviewed.
Results: . The non-opioid medications with the greatest evidence for efficacy in the treatment of chronic spinal cord injury-related pain are drawn from the antiepileptic drug and antidepressant categories though the specific selection must be nuanced to the particular individual patient. More research is required to understand the role of calcitonin, lithium, and marijuana in treating spinal cord injury-related pain.Conclusions: The complex clinical situation of each individual patient must be weighed against the risks and benefits of each medication, as reviewed in this paper, to determine the ideal treatment strategy for chronic spinal cord injury-related pain.

Entities:  

Keywords:  Chronic pain; Gabapentin; Neuropathic pain; Pharmacology; Spinal cord injury; Substance-related disorders

Mesh:

Substances:

Year:  2020        PMID: 32182196      PMCID: PMC8986182          DOI: 10.1080/10790268.2020.1730109

Source DB:  PubMed          Journal:  J Spinal Cord Med        ISSN: 1079-0268            Impact factor:   1.985


  91 in total

Review 1.  Abuse and Misuse of Pregabalin and Gabapentin.

Authors:  Kirk E Evoy; Megan D Morrison; Stephen R Saklad
Journal:  Drugs       Date:  2017-03       Impact factor: 9.546

2.  State of the science on cardiometabolic risk after spinal cord injury: recap of the 2013 Asia pre-conference on cardiometabolic disease.

Authors:  Manon Maitland Schladen; Suzanne L Groah
Journal:  Top Spinal Cord Inj Rehabil       Date:  2014

Review 3.  Risk of falls associated with antiepileptic drug use in ambulatory elderly populations: A systematic review.

Authors:  Mira Maximos; Feng Chang; Tejal Patel
Journal:  Can Pharm J (Ott)       Date:  2017-03-01

4.  Pregabalin and gabapentin in matched patients with peripheral neuropathic pain in routine medical practice in a primary care setting: Findings from a cost-consequences analysis in a nested case-control study.

Authors:  Concepción Pérez; Ana Navarro; María T Saldaña; Xavier Masramón; Javier Rejas
Journal:  Clin Ther       Date:  2010-07       Impact factor: 3.393

5.  Treatments for chronic pain in persons with spinal cord injury: A survey study.

Authors:  Diana D Cardenas; Mark P Jensen
Journal:  J Spinal Cord Med       Date:  2006       Impact factor: 1.985

6.  Efficacy of sustained-release bupropion in neuropathic pain: an open-label study.

Authors:  M R Semenchuk; B Davis
Journal:  Clin J Pain       Date:  2000-03       Impact factor: 3.442

7.  The treatment of spasticity with Delta9-tetrahydrocannabinol in persons with spinal cord injury.

Authors:  U Hagenbach; S Luz; N Ghafoor; J M Berger; F Grotenhermen; R Brenneisen; M Mäder
Journal:  Spinal Cord       Date:  2006-10-17       Impact factor: 2.772

8.  Efficacy of venlafaxine XR for the treatment of pain in patients with spinal cord injury and major depression: a randomized, controlled trial.

Authors:  J Scott Richards; Charles H Bombardier; Catherine S Wilson; Anthony E Chiodo; Larry Brooks; Denise G Tate; Nancy R Temkin; Jason K Barber; Allen W Heinemann; Cheryl McCullumsmith; Jesse R Fann
Journal:  Arch Phys Med Rehabil       Date:  2014-12-17       Impact factor: 3.966

9.  Valproate for treatment of chronic central pain after spinal cord injury. A double-blind cross-over study.

Authors:  A M Drewes; A Andreasen; L H Poulsen
Journal:  Paraplegia       Date:  1994-08

10.  A longitudinal study of the prevalence and characteristics of pain in the first 5 years following spinal cord injury.

Authors:  Philip J Siddall; Joan M McClelland; Susan B Rutkowski; Michael J Cousins
Journal:  Pain       Date:  2003-06       Impact factor: 6.961

View more
  1 in total

1.  DNA Microarray Analysis of Differential Gene Expression in the Dorsal Root Ganglia of Four Different Neuropathic Pain Mouse Models.

Authors:  Hiroyuki Yokoyama; Takashi Hirai; Tetsuya Nagata; Mitsuhiro Enomoto; Hidetoshi Kaburagi; Li Leiyo; Takayuki Motoyoshi; Toshitaka Yoshii; Atsushi Okawa; Takanori Yokota
Journal:  J Pain Res       Date:  2020-11-20       Impact factor: 3.133

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.